Study to Assess Efficacy, Safety, and Tolerability of Brincidofovir Versus Valganciclovir for Prevention of Cytomegalovirus (CMV) Disease in CMV-Seropositive Kidney Transplant Recipients Who Received Antilymphocyte Induction Therapy
试验速览
- 阶段
- 3 期
- 状态
- 终止
- 发起方
- Chimerix
- 入组人数
- 6
- 试验地点
- 3
- 主要终点
- The Incidence of Cytomegalovirus (CMV) Disease
研究概览
简要总结
This was a randomized, double-blind, double-dummy, parallel-group, multicenter study of the efficacy, safety, and tolerability of oral brincidofovir (BCV) versus valganciclovir for the prevention of cytomegalovirus (CMV) disease in CMV-seropositive kidney transplant recipients who received antilymphocyte induction therapy.
详细描述
This was a randomized, double-blind, double-dummy, parallel-group, multicenter study of the efficacy, safety, and tolerability of oral brincidofovir (BCV) versus valganciclovir for the prevention of cytomegalovirus (CMV) disease in CMV-seropositive kidney transplant recipients who received antilymphocyte induction therapy. The study comprised a screening evaluation period (up to 14 days posttransplant), a treatment period (up to 14 weeks posttransplant), and a posttreatment follow-up period (10 weeks, through Week 24 posttransplant).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Triple (Participant, Care Provider, Investigator)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究组 & 干预措施
Treatment 1
100 mg brincidofovir (BCV; one 100 mg tablet) twice weekly plus valganciclovir (vGCV) placebo (2 tablets) once daily.
干预措施: Brincidofovir (Drug)
Treatment 2
900 mg valanciclovir (vGCV; two 450 tablets) once daily plus brincidofovir (BCV) placebo (1 tablet) twice weekly.
干预措施: Valganciclovir (Drug)
结局指标
主要结局
The Incidence of Cytomegalovirus (CMV) Disease
时间窗: 24 weeks (±14 days)
The incidence of CMV disease, which included CMV tissue-invasive disease and CMV syndrome, occurring anytime between randomization and Week 24 posttransplant (±14 days). The proportion of subjects who met this failure endpoint were to be compared between brincidofovir (BCV) and valganciclovir (vGCV) using an unadjusted 95% confidence interval (CI) of the absolute difference between groups (BCV minus vGCV). Number of failures and failure rates were to be presented for each treatment. If the upper bound of the 95% CI fell below 10%, BCV would have demonstrated non-inferiority to vGCV. In the event that the upper bound of the 95% CI fell below 0%, BCV would have additionally demonstrated superiority over vGCV.
次要结局
未报告次要终点